381 related articles for article (PubMed ID: 31314948)
1. Immune landscape of hepatocellular carcinoma microenvironment: Implications for prognosis and therapeutic applications.
Cariani E; Missale G
Liver Int; 2019 Sep; 39(9):1608-1621. PubMed ID: 31314948
[TBL] [Abstract][Full Text] [Related]
2. Construction of a risk score prognosis model based on hepatocellular carcinoma microenvironment.
Zhang FP; Huang YP; Luo WX; Deng WY; Liu CQ; Xu LB; Liu C
World J Gastroenterol; 2020 Jan; 26(2):134-153. PubMed ID: 31969776
[TBL] [Abstract][Full Text] [Related]
3. From bench to bed: the tumor immune microenvironment and current immunotherapeutic strategies for hepatocellular carcinoma.
Fu Y; Liu S; Zeng S; Shen H
J Exp Clin Cancer Res; 2019 Sep; 38(1):396. PubMed ID: 31500650
[TBL] [Abstract][Full Text] [Related]
4. Angiogenesis and immune checkpoint inhibitors as therapies for hepatocellular carcinoma: current knowledge and future research directions.
Hilmi M; Neuzillet C; Calderaro J; Lafdil F; Pawlotsky JM; Rousseau B
J Immunother Cancer; 2019 Nov; 7(1):333. PubMed ID: 31783782
[TBL] [Abstract][Full Text] [Related]
5. Systematic characterization of the tumor microenvironment in Chinese patients with hepatocellular carcinoma highlights intratumoral B cells as a potential immunotherapy target.
Feng Y; Liu L; Li J; Huang J; Xie JH; Menard L; Shi Y; Zhao X; Xie S; Zang W; Tan H; Yang Z; Ni L
Oncol Rep; 2022 Feb; 47(2):. PubMed ID: 34958112
[TBL] [Abstract][Full Text] [Related]
6. Natural Killer Cells and Regulatory T Cells Cross Talk in Hepatocellular Carcinoma: Exploring Therapeutic Options for the Next Decade.
Bozward AG; Warricker F; Oo YH; Khakoo SI
Front Immunol; 2021; 12():643310. PubMed ID: 33995362
[TBL] [Abstract][Full Text] [Related]
7. The immunobiology of hepatocellular carcinoma in humans and mice: Basic concepts and therapeutic implications.
Hou J; Zhang H; Sun B; Karin M
J Hepatol; 2020 Jan; 72(1):167-182. PubMed ID: 31449859
[TBL] [Abstract][Full Text] [Related]
8. The immune contexture of hepatocellular carcinoma predicts clinical outcome.
Foerster F; Hess M; Gerhold-Ay A; Marquardt JU; Becker D; Galle PR; Schuppan D; Binder H; Bockamp E
Sci Rep; 2018 Mar; 8(1):5351. PubMed ID: 29599491
[TBL] [Abstract][Full Text] [Related]
9. Immune-based therapies for hepatocellular carcinoma.
Pinato DJ; Guerra N; Fessas P; Murphy R; Mineo T; Mauri FA; Mukherjee SK; Thursz M; Wong CN; Sharma R; Rimassa L
Oncogene; 2020 Apr; 39(18):3620-3637. PubMed ID: 32157213
[TBL] [Abstract][Full Text] [Related]
10. Tumor Immune Microenvironment and Immunosuppressive Therapy in Hepatocellular Carcinoma: A Review.
Oura K; Morishita A; Tani J; Masaki T
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34071550
[TBL] [Abstract][Full Text] [Related]
11. CD8
Xu C; Lu X; Liu W; Chen A; Meng G; Zhang H; Li B; Zhang Y; Wu J; Wei J
J Transl Med; 2018 May; 16(1):132. PubMed ID: 29784005
[TBL] [Abstract][Full Text] [Related]
12. Immunological landscape and immunotherapy of hepatocellular carcinoma.
Prieto J; Melero I; Sangro B
Nat Rev Gastroenterol Hepatol; 2015 Dec; 12(12):681-700. PubMed ID: 26484443
[TBL] [Abstract][Full Text] [Related]
13. Immunological Microenvironment of Hepatocellular Carcinoma and Its Clinical Implication.
Nishida N; Kudo M
Oncology; 2017; 92 Suppl 1():40-49. PubMed ID: 27764823
[TBL] [Abstract][Full Text] [Related]
14. Immunomodulatory Effects of Current Targeted Therapies on Hepatocellular Carcinoma: Implication for the Future of Immunotherapy.
Lin YY; Tan CT; Chen CW; Ou DL; Cheng AL; Hsu C
Semin Liver Dis; 2018 Nov; 38(4):379-388. PubMed ID: 30357775
[TBL] [Abstract][Full Text] [Related]
15. Combinational Immunotherapy for Hepatocellular Carcinoma: Radiotherapy, Immune Checkpoint Blockade and Beyond.
Lee YH; Tai D; Yip C; Choo SP; Chew V
Front Immunol; 2020; 11():568759. PubMed ID: 33117354
[TBL] [Abstract][Full Text] [Related]
16. Immune suppressive checkpoint interactions in the tumour microenvironment of primary liver cancers.
Zhou G; Boor PPC; Bruno MJ; Sprengers D; Kwekkeboom J
Br J Cancer; 2022 Jan; 126(1):10-23. PubMed ID: 34400801
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapy in hepatocellular carcinoma: the complex interface between inflammation, fibrosis, and the immune response.
Keenan BP; Fong L; Kelley RK
J Immunother Cancer; 2019 Oct; 7(1):267. PubMed ID: 31627733
[TBL] [Abstract][Full Text] [Related]
18. Development of a new patient-derived xenograft humanised mouse model to study human-specific tumour microenvironment and immunotherapy.
Zhao Y; Shuen TWH; Toh TB; Chan XY; Liu M; Tan SY; Fan Y; Yang H; Lyer SG; Bonney GK; Loh E; Chang KTE; Tan TC; Zhai W; Chan JKY; Chow EK; Chee CE; Lee GH; Dan YY; Chow PK; Toh HC; Lim SG; Chen Q
Gut; 2018 Oct; 67(10):1845-1854. PubMed ID: 29602780
[TBL] [Abstract][Full Text] [Related]
19. Metabolic reprogramming of immune cells: Shaping the tumor microenvironment in hepatocellular carcinoma.
Xia Y; Brown ZJ; Huang H; Tsung A
Cancer Med; 2021 Sep; 10(18):6374-6383. PubMed ID: 34390203
[TBL] [Abstract][Full Text] [Related]
20. Delineation of an immunosuppressive gradient in hepatocellular carcinoma using high-dimensional proteomic and transcriptomic analyses.
Chew V; Lai L; Pan L; Lim CJ; Li J; Ong R; Chua C; Leong JY; Lim KH; Toh HC; Lee SY; Chan CY; Goh BKP; Chung A; Chow PKH; Albani S
Proc Natl Acad Sci U S A; 2017 Jul; 114(29):E5900-E5909. PubMed ID: 28674001
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
